Citations

Clear

78 citation(s) found for "Ng, Faye Yu Ci".

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis
Romich, Ellen , Ogdie, Alexis, Stephens‐Shields, Alisa, Merkel, Peter A., Assassi, Shervin , Bujor, Andreea M. , Castelino, Flavia V. , Chung, Lorinda, Evnin, Luke, Gordon, Jessica , Griffith, Melissa, Hant, Faye N. , Harding, Monica, Lakin, Kimberly S., Lebiedz‐Odrobina, Dorota J., Luo, Yiming, McMahan, Zsuzsanna H. , Molitor, Jerry, Moore, Duncan F. , RIchardson, Carrie, Shah, Amit N., Steen, Virginia, Volkmann, Elizabeth R. , Zahn, Carleigh , Sandorfi, Nora , Investigators, for the CONQUER, Chung, Leland W.K. , Bujor, Andreea , Castelino, Flavia V , Frech, Tracy M , Gordon, Jessica K , Hummers, Laura K , Khanna, Dinesh , Mayes, Maureen D , McMahan, Zsuzsanna H , Paik, Julie J , Skaug, Brian , Volkmann, Elizabeth R , Zahn, Carleigh , Chung, Lorinda , Assassi, Shervin , Ogdie, Alexis , Stephens‐Shields, Alisa J. , Merkel, Peter A. , Bernstein, Elana J. , Frech, Tracy , Khanna, Dinesh , Lakin, Kimberly S. , Lebiedz‐Odrobina, Dorota, Makol, Ashima , Mayes, Maureen D. , Molitor, Jerry A., Paik, Julie J. , Richardson, Carrie , Skaug, Brian , Shah, Ami A. , Shah, Ankoor, Steen, Virginia , VanBuren, John M.

Mayo Clinic

Arthritis Care & Research | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80069 | PMID 42007807 Get It

Objective This study aims to identify factors associated with patient global assessment (PtGA) and physician global assessment (PhGA) and discordance between them in systemic sclerosis (SSc). Methods Data from adults with early SSc (<5 years) from the Collaborative National Quality and Efficacy Registry were included. PtGA and PhGA (0–10 scale), clinical evaluations, and patient‐reported outcomes (PROs) were collected every six months. Multivariable mixed‐effects linear regression identified factors associated with PtGA and PhGA using (1) clinical variables and (2) clinical variables plus PROs. Relative weight analysis (RWA) determined the relative importance of each variable. Discordance (≥2 points between PtGA and PhGA) was assessed using multinomial mixed‐effects logistic regression. Results Among 956 patients (83% women, 33% limited disease), mean PtGA and PhGA at enrollment were 4.2 (SD 2.6) and 3.4 (SD 2.0), respectively ( P < 0.001). RWA of clinical variables identified modified Rodnan skin score (mRSS) and New York Heart Association (NYHA) functional class as most influential for both global assessments. After including PROs, PtGA was most influenced by measures of pain, skin symptoms, and physical function. Discordance occurred in 53% of patients (35% PtGA worse, 18% PhGA worse). Worse PtGA was associated with higher overall pain and discomfort. Worse PhGA was associated with higher mRSS, worse NYHA class, higher pain interference, and lower diffusing capacity of the lung. Conclusion Discordance between PtGA and PhGA occurs commonly, highlighting the need for comprehensive symptom management and measurement of disease burden in this complex disease. In SSc, differences in PtGA and PhGA reflect dissimilar weighting of data elements.
Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials
Gallegos, Daphne Rivero, Pais, Faye , Papadopoulou, C., Joerns, Elena K. , Paul, Jisna , Serrano, Jorge Rojas, Kulkarni, T, Gandiga, Prateek C. , So, Ho, Jansen, Marc H.A. , Meunier, Brigitte Bader, Hallowell, Robert W. , Nagaraja, Vivek, Rivero-Gallegos, Daphne , Lan, Ting‐Yuan , Rojas Serrano, Jorge , Kulkarni, Tejaswini , So, Ho , Houghton, Kristin Michelle , Bagri, Narendra Kumar , Bader‐Meunier, Brigitte , Wilfong, Erin M. , Aggarwal, Rohit, Nagaraja, Vivek

Mayo Clinic

Clinical and Experimental Rheumatology | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/rsnsu2 | PMID 41738254 Get It

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
Workload and Fairness: An Overdue Conversation About Clinical Faculty
Bradford, Paul , Hodgin, Faye C, McNicholl, Jenna, Min, Elana A. , Nandwana, Bindiya, McNicholl, Jenna, Strelow, Brittany

Mayo Clinic

The Journal of Physician Assistant Education | October 15, 2025 | Volume: 36 | Issue: 4 | Pages: 333-334

10.1097/jpa.0000000000000713 | PMID 41088512 Get It

American College of Gastroenterology Monograph on Geriatrics and GI
Kane, Sunanda V. , Gardner, Timothy B. , Shaheen, Nicholas J. , Brown, Cristal , Bajaj, Jasmohan S. , Lutz, Megan , Caldera, Freddy, Shaukat, Aasma, Faye, Adam S , Calderwood, Audrey H. , Kochar, Bharati D. , Katz, Seymour , Lee, Linda , Yadlapati, Rena , Wang, Xiao Jing , Nguyen, Linda Anh B. , Caldera, Freddy

Mayo Clinic

American Journal of Gastroenterology | October 3, 2025 | Volume: 120 | Issue: 10S | Pages: S6-S6

10.14309/ajg.0000000000003641 | PMID 41041992 Get It

Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi‐Centre Propensity Score Matched Analysis
Alsakarneh, Saqr , Aburumman, Razan , Bilal, Mohammad , Shaukat, Aasma, Faye, Adam S , Bilal, Mohammad , Alsakarneh, Saqr G , Hashash, Jana G.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 24, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1212-1219

10.1111/apt.70303 | PMID 40704424 Get It

ABSTRACT Introduction Patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). However, the risk of CRC in patients with PSC without IBD remains uncertain. We aimed to evaluate the risk of CRC in patients with PSC without a history of IBD using a large national database. Methods We conducted a retrospective cohort study using the TriNetX database to identify patients ≥ 18 years with PSC. Patients were then divided into two groups, PSC with IBD (PSC‐IBD cohort) and PSC without IBD (PSC non‐IBD cohort), and were matched with patients without a history of PSC or IBD (non‐PSC/non‐IBD group) by using 1:1 propensity score matching. The primary outcome was the risk of first diagnosis of CRC. With censoring applied, Kaplan–Meier analysis with hazard ratios (HRs) and 95% CIs was used to compare time‐to‐event rates at daily time intervals. Results PSC patients without IBD were at increased risk of CRC compared to the non‐PSC/IBD cohort (aHR = 2.91; 95% CI: 1.6–6.0). Patients with PSC and IBD exhibited a higher risk of CRC (aHR = 6.5; 95% CI: 3.78–11.2), especially among the UC cohort (aHR = 6.3; 95% CI: 3.2–12.4). Patients with PSC were at increased risk of various gastrointestinal malignancies (aHR = 10.5; 95% CI: 7.3–15; p < 0.0001), including hepatobiliary cancers, pancreatic cancer, and hepatocellular carcinoma. Discussion Our findings provide real‐world evidence that PSC is an independent risk factor for colorectal cancer, even in the absence of concomitant IBD. These results support the need for further research to determine whether patients with isolated PSC may benefit from tailored CRC surveillance strategies.
Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts
Hanif, Iqtidar, Assassi, Shervin , Mayes, Maureen D. , McMahan, Zsuzsanna H. , Charles, Julio, VanBuren, John M. , Alvey, Jessica S. , Ghaffari, Kimia , Castelino, Flavia V. , Chung, Lorinda, Evnin, Luke, Gordon, Jessica , Hant, Faye N. , Khanna, Dinesh , Lakin, Kimberly S. , Lebiedz‐Odrobina, Dorota, Molitor, Jerry A., Moore, Duncan F. , Sandorfi, Nora , Shah, Ankoor R. , Shanmugam, Victoria K. , Steen, Virginia , Volkmann, Elizabeth R. , Zahn, Carleigh , Chung, Leland W.K. , Castelino, Flavia V , Frech, Tracy M , Gordon, Jessica K , Hummers, Laura K , Khanna, Dinesh , Shanmugam, Victoria K , Volkmann, Elizabeth R , Zahn, Carleigh , Skaug, Brian , Chung, Lorinda , Assassi, Shervin , Mayes, Maureen D , Zhang, Meng , Bernstein, Elana J. , Chung, Lorinda, Frech, Tracy , Luo, Yiming , Makol, Ashima , Richardson, Carrie , Shah, Ami A. , Shah, Ankoor, Skaug, Brian

Mayo Clinic

Arthritis & Rheumatology | May 19, 2025 | Volume: 77 | Issue: 11 | Pages: 1585-1595

10.1002/art.43237 | PMID 40386907 Get It

Objective Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts. Methods All patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non‐RP symptom. Results In GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non‐RP initial symptom, most commonly puffy fingers/hands. Black patients had a non‐RP symptom before RP more commonly than patients in other race and ethnicity categories. Non‐RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity. Conclusion In two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the “warning sign” of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc‐associated autoantibodies, including RNA polymerase III.